

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Natural Beauty Bio-Technology Limited**  
**自然美生物科技有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 00157)**

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO  
THE AUDITED ANNUAL RESULTS ANNOUNCEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2019**

Reference is made to the announcement of Natural Beauty Bio-Technology Limited (the “**Company**”) dated 24 March 2020 in relation to the unaudited annual results for the year ended 31 December 2019 (the “**2019 Unaudited Annual Results Announcement**”), its announcement dated 30 November 2020 in relation to the audited annual results for the year ended 31 December 2019 (the “**2019 Audited Annual Results Announcement**”), its supplemental announcement dated 30 November 2020 in relation to explanation of differences between the unaudited annual results for the year ended 31 December 2019 and the audited annual results for the year ended 31 December 2019 and its announcement dated 2 December 2020 in relation to inside information concerning internal control review (the “**Internal Control Review Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the 2019 Audited Annual Results Announcement and the Internal Control Review Announcement unless the context requires otherwise.

In addition to the information disclosed in the section “Corporate Governance and Other Information” in the 2019 Audited Annual Results Announcement, the Board would like to provide the following additional information pursuant to paragraph 45(5) of Appendix 16 to the Listing Rules in relation to compliance with the CG Code for the year ended 31 December 2019:

The Board is of the view that the Company has met the code provisions set out in the CG Code throughout the year ended 31 December 2019.

However, the Company would like to mention that paragraph C.2 of the CG Code sets out responsibilities of the Board in the aspect of risk management and internal control and in particular, paragraph C.2.3 of the CG Code states that, inter alia, the Board's annual review should consider significant control failings or weaknesses that have been identified during the period. In this regard, the Company has published an announcement on 21 July 2020 (the "**Forensic Review Announcement**") in relation to key findings of Forensic Review, which has identified concerns in the Company's internal control system in certain areas for the year ended 31 December 2019. Further, the Internal Control Review Announcement has disclosed, inter alia, key findings of the Internal Control Review. Moreover, the announcement dated 30 November 2020 in relation to the auditors' letter to audit committee (the "**AC Announcement**") has also set out the Auditors' audit findings in relation to, inter alia, the Forensic Review as well as certain deficiencies in internal control identified during the audit. For further details, please refer to the Forensic Review Announcement, the Internal Control Review Announcement and the AC Announcement.

As disclosed in the Internal Control Review Announcement, the internal control weaknesses as mentioned above have been fully remediated.

The above additional information does not affect other information contained in the 2019 Audited Annual Results Announcement and save as disclosed above, all other information in the 2019 Audited Annual Results Announcement remains unchanged.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Shares on the Stock Exchange has been suspended at the request of the Company since 9:00 a.m. on 25 March 2020 and will remain suspended until further notice. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**Natural Beauty Bio-Technology Limited**  
**LEI Chien**  
*Chairperson*

Hong Kong, 7 December 2020

*As at the date of this announcement, the board of directors comprises Dr. Lei Chien and Mr. Pan Yi-Fan as executive directors; Ms. Lu Yu-Min, Ms. Lin Shu-Hua and Mr. Chen Shou-Huang as non-executive directors; and Mr. Chen Ruey-Long, Mr. Lu Chi-Chant and Mr. Yang Shih-Chien as independent non-executive directors.*